Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 1 - 10 of 40 results.

You searched for : May 2019 to May 2020.

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial Download the PDF version of Article...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial Download the PDF version of Article...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial Download the PDF version of Article...

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorect ...

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial Download the PDF version of Article May 29, 2020 Tokyo,...

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KE ...

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer Download the PDF version of...

Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC ...

Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline Download the PDF version of Article May 28, 2020 Coalition Ignites Strategic...

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Download the PDF version of Article May 25, 2020 ENHERTU is the second innovative...

Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...

Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute Download the PDF version of Article May 22, 2020 First-in-human phase 1...

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer Download the PDF version of Article May 21, 2020 Designation follows recent U.S. Breakthrough Therapy Designations for...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer Download the PDF version of Article May 18, 2020 Refer to Designation based on...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...